CJC-1295 + Ipamorelin Stack: The Gold Standard for Natural GH Release
Why combining GHRH and GHRP creates the most effective growth hormone protocol available
Source: https://indexalabs.com/blog/cjc-1295-ipamorelin-stack-gold-standard-gh-release Abstract: The CJC-1295 No DAC + Ipamorelin combination represents the most widely studied and consistently effective peptide stack for natural growth hormone optimisation. This guide explains the synergistic mechanism, optimal dosing protocol, and why this combination has become the benchmark against which all other GH peptide protocols are measured.
Why Stack Two Peptides? The Synergy Explained
Growth hormone release from the pituitary is controlled by two opposing signals: GHRH (growth hormone-releasing hormone) tells the pituitary to produce and release GH, while somatostatin acts as the brake, inhibiting release. Effective GH optimisation requires amplifying the accelerator while managing the brake.
CJC-1295 No DAC (Mod GRF 1-29) is a GHRH analogue — it mimics the body’s natural “release” signal. It tells the pituitary to produce a pulse of GH. However, used alone, its effectiveness is limited by ambient somatostatin levels.
Ipamorelin is a GHRP (growth hormone-releasing peptide) — it works through the ghrelin receptor to amplify GH release AND suppress somatostatin. This dual action creates an environment where the pituitary can respond maximally to GHRH signalling.
The synergy: When combined, CJC-1295 provides the “go” signal while Ipamorelin removes the brake and amplifies the response. Research demonstrates this combination produces GH pulses 2–3× larger than either peptide alone — a true 1+1=3 scenario.
This mirrors what happens naturally during deep sleep: the hypothalamus releases GHRH while simultaneously reducing somatostatin, creating the body’s largest daily GH surge. The CJC + Ipamorelin stack essentially recreates this optimal hormonal environment on demand.
Why This Is the “Gold Standard” Stack
Clean side effect profile: Unlike other GHRP options (GHRP-6, GHRP-2, Hexarelin), Ipamorelin does not significantly elevate cortisol, prolactin, or appetite. This means the stack delivers GH benefits without the metabolic disruption that other combinations cause.
No desensitisation at standard doses: Hexarelin, the most potent GHRP, causes rapid receptor desensitisation within 4–8 weeks. Ipamorelin shows minimal desensitisation even at 16+ weeks, making it suitable for extended protocols.
Pulsatile release: The No DAC version of CJC-1295 has a half-life of ~30 minutes, producing a clean GH pulse that rises and falls naturally. This contrasts with CJC-1295 with DAC, which creates a sustained “bleed” of GH — less physiological and associated with more side effects.
Predictable dosing: The response curve is linear and consistent. 100 mcg of each produces a reliable GH pulse in the majority of subjects, making it easy to titrate and adjust.
Extensive research history: This combination has been studied longer and more extensively than any other peptide stack, providing a substantial body of literature on safety and efficacy.
Complete Dosing Protocol
Starter Protocol (Weeks 1–2):
- CJC-1295 No DAC: 50 mcg
- Ipamorelin: 100 mcg
- Combined in the same syringe
- Frequency: 1–2 times daily (pre-bed minimum)
- Purpose: Assess tolerance, establish baseline response
Standard Protocol (Weeks 3–12):
- CJC-1295 No DAC: 100 mcg
- Ipamorelin: 100–200 mcg
- Combined in the same syringe
- Frequency: 2–3 times daily
- Duration: 12–16 weeks
Optimal Timing:
- Pre-bed (most important): 30–60 minutes before sleep on an empty stomach. Amplifies the natural nocturnal GH surge.
- Morning fasted: Upon waking, before any food. Wait 30–60 minutes before eating.
- Post-workout (if using 3x daily): Within 15 minutes of completing exercise, when GH sensitivity is elevated.
Critical Rules:
- Always inject on an empty stomach (minimum 2 hours fasted)
- Do not consume carbohydrates or fats for 30–60 minutes post-injection — insulin blunts GH release
- Protein alone has minimal impact on the GH pulse
- Both peptides can be drawn into and injected from the same syringe
Reconstitution:
- CJC-1295 No DAC (2 mg vial): Add 1 mL BAC water → 100 mcg per 5 units on insulin syringe
- Ipamorelin (5 mg vial): Add 2 mL BAC water → 250 mcg per 10 units
- Store reconstituted vials refrigerated, use within 28 days
Cycling: 12–16 weeks on, 4–8 weeks off. The off period is precautionary — maintaining receptor sensitivity and allowing the body to recalibrate.
Results Timeline: What to Expect
Days 1–3: Improved sleep quality. Deeper, more restorative sleep with vivid dreams. This is the most immediate and consistent effect — often noticed within the first 2–3 injections.
Weeks 1–2: Enhanced recovery. Reduced muscle soreness after training, faster return to baseline. Some users report improved skin hydration and a general sense of wellbeing.
Weeks 3–4: Body composition shifts begin. Subtle reduction in subcutaneous fat, particularly around the midsection. Improved muscle pumps during training. Nails and hair may grow faster.
Weeks 6–8: Peak recomposition effects. Measurable changes in body composition — fat loss paired with lean mass preservation or gain. Skin quality improvement becomes noticeable (thickness, elasticity, hydration). Joint comfort improves.
Weeks 8–16: Sustained optimisation. Continued gradual improvements in body composition, recovery, and overall vitality. Benefits tend to plateau around week 12–16, which signals an appropriate time for a break.
Blood Markers: IGF-1 levels typically increase 20–40% from baseline when measured at week 6–8. This confirms the biological response and can guide dosage adjustments.
Important Expectations: This stack produces gradual, sustainable changes — not overnight transformations. The results compound over time and closely mimic what optimised natural GH production would deliver. Think “turning the clock back 10–15 years on GH output” rather than bodybuilding-dose effects.
Advanced Stacking Options
CJC + Ipamorelin + Tesamorelin (Fat Loss Focus):
- Add Tesamorelin 1–2 mg daily (single injection, any time)
- Tesamorelin provides additional GHRH stimulus specifically targeting visceral fat
- Best for subjects with significant abdominal adiposity
CJC + Ipamorelin + BPC-157 (Recovery Focus):
- Add BPC-157 250–500 mcg daily
- Combines systemic GH benefits with targeted tissue repair
- Excellent for active individuals managing injuries or chronic inflammation
CJC + Ipamorelin + MK-677 (Sustained GH Focus):
- Oral MK-677 (ibutamoren) 12.5–25 mg daily provides 24-hour baseline GH elevation
- CJC + Ipamorelin pulses on top of this baseline
- Maximum GH output protocol — monitor blood glucose carefully
- Not recommended for beginners
CJC + Ipamorelin + MOTS-C (Longevity Focus):
- Add MOTS-C 10 mg weekly
- Combines GH optimisation with mitochondrial enhancement
- Addresses multiple aging pathways simultaneously
Note: More is not always better. The standard CJC + Ipamorelin stack alone delivers significant benefits for the majority of research subjects. Advanced stacking should only be considered after establishing a successful baseline with the core combination.